|[September 02, 2013]
Research and Markets: Protein Kinase Inhibitors in Oncology Drug Pipeline Update 2013: Today there are 305 Companies plus Partners Developing 615 Protein Kinase Inhibitors Drugs
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/lb9n2k/protein_kinase)
has announced the addition of the "Protein
Kinase Inhibitors in Oncology Drug Pipeline Update 2013" report
to their offering.
Protein kinase inhibitors such as Gleevec, Iressa and Tarceva have
allowed the biotechnology industry to deliver on the promise of targeted
cancer drugs. However, these three successful drugs are just the top of
an emerging line of therapy. Given the fact that they all target
tyrosine kinases and that kinase mutations can cause patients to become
resistant to these drugs, there is plenty of room for more competition.
There are today 305 companies plus partners developing 615 PKI drugs in
2089 developmental projects in cancer. In addition, there are
suspended drugs and the accumulated number of ceased drugs over the last
years amount to another 332 drugs. Protein Kinase Inhibitors In Oncology
Drug Pipeline Update lists all drugs and gives you a progress analysis
on each one of them. Identified drugs are linked to 237 different
targets. All included targets have been cross-referenced for the
presence of mutations associated with human cancer. To date 230 out of
the 235 studied drug targets so far have been recorded with somatic
mutations. The software application lets you narrow in on these
mutations and links out to the mutational analysis for each of the drug
targets for detailed information. All drugs targets are further
categorized on in the software application by 45 classifications of
molecular function and with pathway referrals to BioCarta, KEGG,
NCI-Nature and NetPath.
Drug Pipeline Update at a Glance
Includes more than 305 principal companies plus their collaborators.
There is direct access from inside the application to web pages of all
The identity of available biological structures on 178 drug targets was
retrieved from the RCSB Protein Databank for you to easily review the
3014 structures available today among drug targets.
For more information visit http://www.researchandmarkets.com/research/lb9n2k/protein_kinase
About Research and Markets
Research and Markets is the world's leading source for international
market research reports and market data. We provide you with the latest
data on international and regional markets, key industries, the top
companies, new products and the latest trends.
[ Back To Technology News's Homepage ]